POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy

• Yan‐Xing Chen,
• Zi‐Xian Wang,
• Shu‐Qiang Yuan,
• Teng‐Jia Jiang,
• You‐Sheng Huang,
• Rui‐Hua Xu,
• Feng Wang,
• Qi Zhao

Affiliations

Yan‐Xing Chen

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

Zi‐Xian Wang

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

Shu‐Qiang Yuan

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

Teng‐Jia Jiang

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

You‐Sheng Huang

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

Rui‐Hua Xu

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

Feng Wang

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China

Qi Zhao

State Key Laboratory of Oncology in South China, Sun Yat‐sen University Cancer Center Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 China